# US 2026/0108612 A1 · Beta-peptides and beta-peptide hydrogels

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0108612 A1
- Document ID: US20260108612A1
- Status: Published application
- Kind: A1
- Application number: 18/865,896
- Filed: 2023-05-17
- Published: 2026-04-23
- Earliest claimed: 2022-05-17
- Assignees: Monash University
- Applicants: Monash University
- Inventors: Marie-Isabel Aguilar; Mark Del Borgo; Ketav Kulkarni; Andrew Hong; John Forsythe; Bradley Broughton; Helena C. Parkington; Seyedeh Mahnaz Modarresi Saryazdi; Meg McFetridge
- Web page: https://patentgrep.com/patent/US20260108612A1

## CPC

- A61K 47/42: Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34)
- C07C 237/22: having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated (peptides C07K)
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61L 27/22: Polypeptides or derivatives thereof {, e.g. degradation products}
- A61L 27/52: Hydrogels or hydrocolloids
- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C07D 209/14: Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D 307/33: in position 2, the oxygen atom being in its keto or unsubstituted enol form
- C07K 5/0202: {containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids}
- C07K 5/0817: {the first amino acid being Arg}
- C07K 5/0819: {with the first amino acid being acidic}
- C07K 5/1016: {and aromatic or cycloaliphatic}
- C07K 7/06: having 5 to 11 amino acids
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention relates to β-peptides and hydrogels comprising the β-peptides. The hydrogels may further comprise a therapeutic cargo encapsulated within the hydrogel. Methods of preparing the hydrogels, and methods for the use of the hydrogels are also described.

## Claims

### Claim 1

A β-peptide of formula (I):
wherein:
R1 is selected from —C1-20alkyl, —C2-20alkenyl, —C2-20alkynyl, —OC1-20alkyl, —OC2-20alkenyl and —OC2-20alkynyl;
R2 is selected from —H, —OR10a, —SR10a, —N(R11a)2, —NH(C═NH)NH2, cycloalkyl, aryl, heterocyclyl, and heteroaryl, where each cycloalkyl, aryl, heterocyclyl, and heteroaryl is unsubstituted or is substituted with one or more groups selected from —OH, —NH2, —NHC1-3alkyl, —OC1-3alkyl, —SH, —SC1-3alkyl, —CO2H, —CO2C1-3alkyl, —CONH2 and —CONHC1-3alkyl, or R2 has the following structure (A):
R3, R4, R5, R6 and R8 are each independently selected from —H, —R9, —C1-6alkylR9, —C2-6alkenylR9 and —C2-6alkynylR9;
or R2 and R6 together form a heterocyclic ring;
R7 is selected from —H, —OR10a, —SR10a, —N(R11a)2, —NH(C═NH)NH2, cycloalkyl, aryl, heterocyclyl, and heteroaryl, where each cycloalkyl, aryl, heterocyclyl, and heteroaryl is unsubstituted or is substituted with one or more groups selected from —OH, —NH2, —NHC1-3alkyl, —OC1-3alkyl, —SH, —SC1-3alkyl, —CO2H, —CO2C1-3alkyl, —CONH2 and —CONHC1-3alkyl;
or R7 and R8 together form a heterocyclic ring;
R9 is selected from —H, —OR10, —SR10, —N(R11)2, —C(O)R12, —NH(C═NH)NH2, cycloalkyl, aryl, heterocyclyl, and heteroaryl, where each cycloalkyl, aryl, heterocyclyl, and heteroaryl is unsubstituted or is substituted with one or more groups selected from —OH, —NH2, —NHC1-3alkyl, —OC1-3alkyl, —SH, —SC1-3alkyl, —CO2H, —CO2C1-3alkyl, —CONH2 and —CONHC1-3alkyl;
R10 is selected from —H, —C1-6alkyl, —C2-6alkenyl, —C2-6alkynyl, —C(O)C1-20alkyl, —C(O)C1-20alkenyl, —C(O)C1-20alkynyl, —C(O)C1-6alkylR14, an α-peptide having 1 to 10 α-amino acid residues and an imaging agent;
R10a is selected from —H, —C1-6alkyl, —C2-6alkenyl, —C2-6alkynyl, —C(O)C1-6alkyl, —C(O)C2-6alkenyl, and —C(O)C2-6alkynyl;
each R11 is independently selected from —H, —C1-6alkyl, —C1-6alkylN(R13)2, μ-C1-6alkylNR13R14, —C2-6alkenyl, —C2-6alkynyl, —C(O)C1-20alkyl, —C(O)C1-20alkenyl, —C(O)C1-20alkynyl, —C(O)C1-6alkylR14, an α-peptide having 1 to 10 α-amino acid residues and an imaging agent;
each R11a is independently selected from —H, —C1-6alkyl, —C2-6alkenyl, —C2-6alkynyl, —C(O)C1-6alkyl, —C(O)C2-6alkenyl, —C(O)C2-6alkynyl;
R12 is selected from —OH, —OR10 and —N(R11)2;
each R13 is independently selected from —H and —C1-6alkyl;
R14 is an α-peptide having 1 to 10 α-amino acid residues or an imaging agent;
or a pharmaceutically acceptable salt thereof;
and wherein one of R1, R2, R3, R4, R8, R6 and R8 comprise a C8-20alkyl group, a C8-20alkenyl group or a C8-20alkynyl group.

### Claim at position 2

2-32. (canceled)

### Claim 33 (depends on 1)

The β-peptide according to claim 1 wherein R1 is C1-20alkyl.

### Claim 34 (depends on 33)

The β-peptide according to claim 33 wherein R1 is methyl.

### Claim 35 (depends on 1)

The β-peptide according to claim 1 wherein R2 is —OH or wherein R2 together with R6 forms a heterocycle.

### Claim 36 (depends on 35)

The β-peptide according to claim 35, wherein R2 together with R6 together form a lactone.

### Claim 37 (depends on 36)

The β-peptide according to claim 36, wherein the β-peptide has the formula:

### Claim 38 (depends on 1)

The β-peptide according to claim 1 wherein one or more of R3, R4, R5, R6 and R8 corresponds to an amino acid side chain, where each amino acid side chain may be the same or different.

### Claim 39 (depends on 1)

The β-peptide according to claim 1 wherein one or more of R3, R4, R5 and R6 corresponds to a hydrophilic amino acid side chain, where each hydrophilic amino acid side chain may be the same or different.

### Claim 40 (depends on 1)

The β-peptide according to claim 1 wherein one of R3, R4, R7, R6 or R8 comprises a C8-20alkyl group.

### Claim 41 (depends on 1)

The β-peptide according to claim 1 wherein one or more of R3, R4, R5, R6 comprises an α-peptide having 1 to 10 α-amino acid residues.

### Claim 42 (depends on 1)

The β-peptide according to claim 1 wherein one or more of R3, R4, R5, R6 comprises an imaging agent.

### Claim 43 (depends on 1)

The β-peptide according to claim 1, wherein the β-peptide is selected from the following:
No.
Structure
1
2
3
4
5
6
7

### Claim 44 (depends on 1)

A hydrogel comprising one or more β-peptides of formula (I) according to claim 1.

### Claim 45 (depends on 44)

The hydrogel according to claim 44 wherein the hydrogel comprises one β-peptide of formula (I) or two β-peptides of formula (I) which are a first β-peptide and a second β-peptide.

### Claim 46 (depends on 45)

The hydrogel according to claim 45 wherein the hydrogel comprises a first β-peptide and a second β-peptide in a ratio of 3:1, 2:1, 1:1, 1:2, or 1:3 by weight.

### Claim 47 (depends on 44)

The hydrogel according to claim 44 wherein the hydrogel further comprises a therapeutic cargo encapsulated within the hydrogel.

### Claim 48 (depends on 47)

The hydrogel according to claim 47 wherein the therapeutic cargo is selected from a small molecule drug, a macromolecular drug and a cell.

### Claim 49 (depends on 48)

The hydrogel according to claim 48 wherein the cell is a stem cell.

### Claim 50 (depends on 44)

The hydrogel according to claim 44 wherein the hydrogel is injectable.

### Claim 51 (depends on 1)

A method for treating stroke comprising administering to a patient in need thereof a hydrogel comprising:
one or more β-peptides of formula (I) according to claim 1; and
a stem cell encapsulated within the hydrogel.
